

### AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims.

1. (currently amended) An isolated humanized antibody or a fragment thereof that (a) immunoreacts with an epitope present on human tissue factor ("TF") that comprises Trp45 and (b) inhibits the binding of human coagulation factor VIIa to human TF.

2-3. cancelled

4. (currently amended) The isolated humanized antibody or antibody fragment of claim 1, wherein the humanized antibody or fragment is a Fab fragment.

5. (currently amended) The isolated humanized antibody or antibody fragment of claim 1, wherein the humanized antibody or fragment thereof is a F(ab)<sub>2</sub> fragment.

6. (currently amended) The isolated humanized antibody or fragment of claim 1, wherein the humanized antibody or fragment is a F(ab')<sub>2</sub> fragment.

7. (currently amended) The isolated humanized antibody or fragment of claim 1, wherein the humanized antibody is a single chain Fv fragment.

8-10. cancelled

11. (currently amended) The isolated humanized antibody or fragment of claim 1, wherein the human framework amino acid sequences of the humanized antibody or fragment are derived from a human antibody that immunoreacts with a second epitope present on human TF.

12-14. cancelled

15. (currently amended) A pharmaceutically acceptable composition comprising a therapeutically effective amount of the isolated humanized antibody or fragment of claim 1.

16. cancelled

17. (withdrawn -- currently amended) A method for treating a FVIIa/TF related disorder in a human comprising administering a therapeutically effective amount of a humanized antibody or fragment thereof that (a) immunoreacts with an epitope on human TF that comprises Trp45 and (b) inhibits the binding of human coagulation factor VIIa to human TF.

18-29. cancelled

30. (currently amended) A cell that produces a humanized antibody or fragment thereof that (a) immunoreacts with an epitope on human tissue factor ("TF") that comprises Trp45 and (b) inhibits the binding of human coagulation factor VIIa to human TF.

31. (original) The cell of claim 30, wherein the cell is a mammalian cell.

32. (previously presented) The cell of claim 30, wherein the cell is a cell derived from a cell line selected from the group consisting of CHO, BHK, HEK293, P3X63-Ag8, P3X63-AG8.653, PERC6, NS0, YB2/0, P3/NS1-Ag4-1 (NS-1), Sp2/0-Agl4 and S194/5.XXO.Bu.1.

33. cancelled